NASDAQ:PODD - Insulet Stock Price, Forecast & News

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings data on Tuesday, November, 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.02. The medical instruments supplier earned $192.12 million during the quarter, compared to analyst estimates of $179.50 million. Insulet had a return on equity of 10.34% and a net margin of 2.38%. The business's revenue for the quarter was up 27.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.03 EPS. View Insulet's Earnings History.

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insulet.

Insulet will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

17 brokerages have issued 12-month price targets for Insulet's shares. Their forecasts range from $100.00 to $213.00. On average, they anticipate Insulet's stock price to reach $162.06 in the next year. This suggests that the stock has a possible downside of 25.1%. View Analyst Price Targets for Insulet.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.

News articles about PODD stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Insulet earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), DexCom (DXCM), Tandem Diabetes Care (TNDM), Roku (ROKU), Splunk (SPLK), salesforce.com (CRM), Veeva Systems (VEEV) and Adobe (ADBE).

Insulet's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Capital Research Global Investors (10.81%), Capital World Investors (6.47%), William Blair Investment Management LLC (2.59%), Fred Alger Management LLC (2.34%), Alliancebernstein L.P. (1.43%) and Geode Capital Management LLC (1.15%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including CSS LLC IL, Capital Research Global Investors, Fred Alger Management LLC, Goldman Sachs Group Inc., Alliancebernstein L.P., Jennison Associates LLC, Eagle Asset Management Inc. and Russell Investments Group Ltd.. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

PODD stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Renaissance Technologies LLC, Beacon Investment Advisory Services Inc., Sumitomo Mitsui Trust Holdings Inc., Capital International Investors, UBS Asset Management Americas Inc., Swiss National Bank and SG Americas Securities LLC. View Insider Buying and Selling for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $216.44.

Insulet has a market capitalization of $13.38 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

The official website for Insulet is http://www.insulet.com/.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]